Matthew L. Posard sold $2M of HALO stock

Matthew L. Posard, Dir of Halozyme Therapeutics, Inc. (HALO), sold 18,996 shares of HALO stock worth $2M, per an SEC Form 4 filed Sep 17, 2026.

The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.

The trade happened on Sep 16, 2026, 1 day before it was made public.

HALO has moved -7.2% since the trade date, from $108.44 to $100.67 (Nov 12, 2026 close).